A 19-year-old Canadian man becomes the first human cured through prime gene editing after doctors corrected a rare genetic ...

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

The U.S. Food and Drug Administration approved the first cell-based gene therapies for sickle cell disease, including the ...

For the first time, the tools to rewrite human biology are moving from speculative fiction into regulated clinics and consumer-facing startups. Gene editing, once confined to rare diseases and lab ...

A Bay Area biochemist has launched a new company to further research on gene editing on human embryos. Lucas Harrington said the research will focus on using the technology to prevent genetic disease ...

A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way ...

Two studies published in Nature Medicine June 11 contribute to a small body of literature suggesting cells edited with CRISPR-Cas9 may cause cancer. Here are five things to know about the studies and ...

Tools like CRISPR-Cas9 are creating new opportunities for innovation in St. Louis, as well as risks around IP protection and regulation.

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr ...

When you think of the “Make America Healthy Again” (MAHA) movement, you might picture fertile soil, organic farms, and homeopathic remedies. For some, that vision is a welcome change; for others, it ...